<DOC>
	<DOCNO>NCT02088684</DOCNO>
	<brief_summary>The purpose trial explore clinical utility three investigational agent HR+ , HER2- breast cancer . LEE011 ( CDK4/6 inhibitor ) , BKM120 ( PI3K-pan class I-inhibitor ) BYL719 ( PI3K-alpha specific class I inhibitor ) combination fulvestrant . This multi-center , open-label Phase Ib/II study . The Phase Ib portion study dose escalation estimate MTD and/or RP2D three regimen : LEE011 fulvestrant ; LEE011 BKM120 fulvestrant ; LEE011and BYL719 fulvestrant . The Phase II portion study randomize study assess anti-tumor activity well safety tolerability LEE011 fulvestrant LEE011 BKM120 fulvestrant , LEE011 BYL719 fulvestrant patient ER+/HER2- locally advance metastatic breast cancer . Approximately 216 adult woman ER+/HER2- locally advance metastatic breast cancer enrol .</brief_summary>
	<brief_title>Study LEE011 With Fulvestrant BYL719 BKM120 Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal , Hormone receptor positive ( HR+ ) , HER2 negative breast cancer Unlimited number line endocrine therapy two line cytotoxic chemotherapy metastatic setting ( Phase Ib ) Unlimited number line endocrine therapy one line cytotoxic chemotherapy metastatic setting ( Phase II ) HER2overexpression patient 's tumor tissue Inadequate bone marrow function evidence endorgan damage Severe uncontrolled medical issue Diabetes mellitus Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hormone receptor positive , HER2 negative</keyword>
</DOC>